Cibinqo

RSS

abrocitinib

Authorised
This medicine is authorised for use in the European Union.

Overview

Cibinqo is a medicine for treating adults with moderate to severe atopic dermatitis (also known as eczema, when the skin is itchy, red and dry). It is used in patients for whom treatment applied directly to the skin cannot be used or is not sufficient.

Cibinqo contains the active substance abrocitinib.

This EPAR was last updated on 17/12/2021

Authorisation details

Product details
Name
Cibinqo
Agency product number
EMEA/H/C/005452
Active substance
Abrocitinib
International non-proprietary name (INN) or common name
abrocitinib
Therapeutic area (MeSH)
Dermatitis, Atopic
Anatomical therapeutic chemical (ATC) code
D11AH
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG 
Date of issue of marketing authorisation valid throughout the European Union
09/12/2021
Contact address

Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Product information

09/12/2021 Cibinqo - EMEA/H/C/005452 -

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other dermatological preparations

Therapeutic indication

Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating
1 rating